Skip to main content
Acerus Pharmaceuticals Corporation logo

Acerus Pharmaceuticals Corporation — Investor Relations & Filings

Ticker · ASPCF ISIN · CA00444G4051 LEI · 5493002UNYD7HWVNFY70 TSX Manufacturing
Open in API
Filings indexed 133 across all filing types
Latest filing 2023-03-14 Delisting Announcement
Country CA Canada
Listing TSX ASPCF

About Acerus Pharmaceuticals Corporation

https://www.aceruspharma.co/

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development, commercialization, and distribution of innovative branded products designed to improve the patient experience. The company leverages scientific research to address unmet medical needs, primarily within the therapeutic areas of men's and women's health. A core focus includes treatments for male hypogonadism, featuring the lead product Natesto, a formulation for testosterone delivery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Delisting Announcement Classification · 95% confidence The document is a press release announcing the commencement of a court-approved sale and investment solicitation process (SISP) for Acerus Pharmaceuticals Corporation under the Companies' Creditors Arrangement Act (CCAA) proceedings. It references court orders, the appointment of a monitor, and details about the sale process and deadlines. It also mentions the delisting of the company's shares from the Toronto Stock Exchange. The document does not contain financial statements, audit information, or detailed financial results. It is primarily an announcement related to restructuring and sale process under court supervision, which aligns with a Delisting Announcement due to the explicit mention of delisting effective March 3, 2023. The document length is under 5,000 characters and is an announcement rather than a full report. Therefore, the most appropriate classification is Delisting Announcement (DLST).
2023-03-14 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new loan agreement between Acerus Pharmaceuticals Corporation and First Generation Capital. It details the terms of the loan, interest rate, repayment schedule, and related corporate governance considerations. There is no financial statement data, no quarterly or annual report content, no audit information, and no regulatory certification. The document focuses on financing activity and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6840 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2022-12-22 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report for the third quarter ended September 30, 2022, including comprehensive financial results, management commentary, and financial statements. It contains actual financial data such as revenue, expenses, EBITDA, net loss, and balance sheet items. The presence of quarterly financial results, detailed analysis, and financial statements indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-11-15 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion & Analysis of Acerus Pharmaceuticals Corporation For the three and nine months ended September 30, 2022,' indicating it is a Management Discussion and Analysis (MD&A) report. It contains detailed discussion of financial condition, operating results, business prospects, risks, and forward-looking statements for the interim period ending September 30, 2022. The text references unaudited condensed interim consolidated financial statements prepared under IFRS and discusses financial performance and strategic initiatives. The length of the document (15,000 characters) and the presence of substantive financial and operational analysis confirm it is a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-11-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS' signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial data or substantive financial analysis. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3346 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-11-14 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CFO regarding the interim financial filings for the period ended September 30, 2022. It references the interim financial report and interim MD&A but does not contain the actual financial data or analysis itself. The document is a formal attestation of the accuracy and fairness of the interim filings, consistent with regulatory certification requirements under National Instrument 52-109. Given the document length is only 3310 characters and it is primarily a certification letter, it fits the criteria for a Regulatory Filing (RNS) rather than an Interim Report (IR) or other financial report. Therefore, the correct classification is Regulatory Filings (RNS).
2022-11-14 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.